Mammella HER2+: gli antibody drug conjugate

Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugateПодробнее

【HER2 inhibitors】Trastuzumab(Herceptin®), Pertuzumab, Lapatinib, Antibody-drug conjugates (KADCYLA®)Подробнее

HER2+ Breast Cancer: Evolution of Antibody-Drug ConjugatesПодробнее

Dr. Hong's Biotechnology Lecture 04: Cancers and Antibody Drug ConjugateПодробнее

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology ConferenceПодробнее

Antibody–Drug Conjugates for Solid Tumors: Progress, Possibilities, and Implications for CareПодробнее

antibody drug conjugateПодробнее

Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in ReviewПодробнее

Comparative Analysis of Anti-HER2 Antibody-Drug Conjugates in Tumor Spheroid ModelsПодробнее

Gli ADCs nei carcinomi HER2 lowПодробнее

Clinical Perspectives on HER2-Targeted Antibody-Drug Conjugates: Treatment-Related Adverse EventsПодробнее

Antibody Drug Conjugates: CharacterizationПодробнее

Benefit of Antibody Drug Conjugate T-DM1 in HER2+ BCПодробнее

Manufacturing concepts for antibody-drug conjugates | WebinarПодробнее

What are antibody-drug conjugates and how do they work against cancer?Подробнее

Dr. Hong's Biotechnology: Antibody Drug ConjugateПодробнее

Antibody-drug conjugates in gynecological cancersПодробнее

Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid TumorsПодробнее

Study of DS-8201a in HER2-Low, Unresectable and/or Metastatic Breast CancerПодробнее

Sanofi – Antibody – Drug ConjugatesПодробнее